NCT02412228 · OUTCOME

Evaluation of the Toxicities Associated With Ixazomib With Metronomic Cyclophosphamide and Dexamethasone.

Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma · Source last updated 2025-10-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Assessed at baseline and end of study, up to 2 years, end of study reported

Groups in this outcome

Ixazomib Regimen

Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18 Maintenance: Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years Ixazomib: Cycle 1: Ixazomib: 4mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Maintenance: Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years Cyclophosphamide: Cycle 1: Cyclophosphamide: 50 mg/day continuous daily Cycles 2-6: Cyclophosphamide: 50 mg/day continuous daily Dexamethasone: Cycle 1: Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Ixazomib Regimen	12

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ixazomib Regimen	12	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
12

denoms

counts
group Id
OG000
value
12
units
Participants

groups

description
Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18 Maintenance: Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years Ixazomib: Cycle 1: Ixazomib: 4mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Maintenance: Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years Cyclophosphamide: Cycle 1: Cyclophosphamide: 50 mg/day continuous daily Cycles 2-6: Cyclophosphamide: 50 mg/day continuous daily Dexamethasone: Cycle 1: Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18
id
OG000
title
Ixazomib Regimen

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Assessed at baseline and end of study, up to 2 years, end of study reported

title

Evaluation of the Toxicities Associated With Ixazomib With Metronomic Cyclophosphamide and Dexamethasone.

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice